Antifungal drug may alter levels of experimental cancer pill

NCT ID NCT07649954

Recruiting now Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests whether taking the antifungal drug itraconazole changes how the body processes nacresertib, an experimental cancer medication. Healthy adults aged 18 to 65 will receive nacresertib alone and then again with itraconazole to compare drug levels in the blood. The goal is to understand potential drug interactions and ensure safety before testing nacresertib in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nacresertib and Itraconazole
What this could lead to: If successful, this study could help determine safe dosing of nacresertib when taken with common antifungal medications.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. Results may not predict effects in people with cancer or other illnesses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Acpru /Id# 282339
RECRUITING

Grayslake, Illinois, 60030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.